IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE

被引：0
|
作者：
Villa, M. R. [1 ]
Gagliardi, A. [1 ]
Della Cioppa, P. [1 ]
Esposito, M. [1 ]
Lucania, A. [1 ]
Izzo, G. Nitrato [1 ]
Improta, S. [1 ]
Mastrullo, L. [1 ]
机构：
[1] ASL Napoli 1 Ctr, UOC Ematol PO San Gennaro, Naples, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P111
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [1] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Villa, M. R.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Izzo, G. Nitrato
    Gagliardi, A.
    Mastrullo, L.
    HAEMATOLOGICA, 2017, 102 : 766 - 767
  • [2] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 103 - 104
  • [3] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Esposito, M.
    Gagliardi, A.
    Lucania, A.
    Izzo, G. Nitrato
    Villa, M. R.
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2015, 39 : S52 - S53
  • [4] IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE
    Brechemier, D.
    Comont, T.
    Bertoli, S.
    Dutertre, M.
    Recher, C.
    Adoue, D.
    Beyne-Rauzy, O.
    LEUKEMIA RESEARCH, 2015, 39 : S46 - S46
  • [5] Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine
    Laribi, Kamel
    Bolle, Delphine
    Alani, Mustafa
    Ghnaya, Habib
    Besancon, Anne
    Farhi, Jonathan
    Mheidly, Kayane
    Denizon, Nathalie
    de Materre, Alix Baugier
    CANCER MEDICINE, 2019, 8 (05): : 2188 - 2195
  • [6] Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)
    Fabiani, Emiliano
    Calabrese, Chiara
    Niscola, Pasquale
    Balleari, Enrico
    Molteni, Alfredo
    Finelli, Carlo
    Falconi, Giulia
    Fenu, Susanna
    Fianchi, Luana
    Criscuolo, Marianna
    Salvi, Flavia
    Lavorgna, Serena
    Buccisano, Francesco
    Maurillo, Luca
    Lo Coco, Francesco
    Cilloni, Daniela
    Voso, Maria Teresa
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 954 - 957
  • [7] AZACITIDINE: AN ALTERNATIVE TREATMENT REGIMEN FOR ELDERLY HIGH-RISK MYELODYSPLASTIC PATIENTS
    Ramakrishna, R.
    Alexander, W.
    Sarathy, K.
    HAEMATOLOGICA, 2013, 98 : 583 - 584
  • [8] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 120 - 120
  • [9] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395
  • [10] IRON CHELATION THERAPY FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Yeh, Su-Peng
    Yang, Yang-Sheng
    Yao, Chao-Yuan
    Peng, Ching-Tien
    HEMOGLOBIN, 2009, 33 (05) : 339 - 345
12345